Amcinonide

Amcinonide is an inhibitor of NO release (IC50 = 3.38 nM) . Amcinonide inhibits NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. Amcinonide reduces the numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. Amcinonide induces a selective reduction in expression of Ia antigens. Amcinonide can also be studied in research for eczematous dermatitis[1][2][3].

Product Specifications

CAS Number

[51022-69-6]

Product Name Alternative

CL-34699

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Glucocorticoid Receptor; Interleukin Related; NO Synthase; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Amcinonide.html

Purity

99.11

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@@]3(C(COC(C)=O)=O)[C@@](OC4(O3)CCCC4)([H])C[C@@]1([H])[C@]5([H])CCC6=CC(C=C[C@]6(C)[C@@]5(F)[C@@H](O)C2)=O

Molecular Formula

C28H35FO7

Molecular Weight

502.57

Precautions

H315, H319, H320

References & Citations

[1]Hong J, et al. Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor. Immunopharmacol Immunotoxicol. 2012 Dec;34 (6) :912-918.|[2]Berman B, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol. 1983 Mar;80 (3) :168-171.|[3]Bickers D. R. (1984) . A comparative study of amcinonide and halcinonide in the treatment of eczematous dermatitis. Cutis, 34 (2), 190–194.